SLDB - Solid Corp Revenue Growth YoY (Last 12 Months)

Solid Biosciences Inc. (SLDB) US centers are developing innovative therapies for muscular dystrophy. The year-over-year relative revenue growth rate (12 months) reflects the current market valuation, with the value holding at 0.00. The business is entirely non-cyclical and depends solely on tests. Massive latent demand in the rare genetic pathology segment will ensure rapid growth of the company's client base.
Solid Biosciences Inc (SLDB) - metric breakdowns and financial figures

This indicator measures revenue dynamics over a rolling year, allowing for an assessment of business expansion rates relative to the previous period by calculating the difference in income. For Solid Biosciences Inc. (SLDB), whose success depends on gene therapy clinical trials, the 0.00 value in year-over-year (TTM) revenue change reflects the company's current stage of development, where financial growth is secondary to drug safety.